Development of indicators to assess quality of care for prostate cancer

Nupur Nag, Jeremy Millar, Ian D. Davis, Shaun Costello, James B. Duthie, Stephen Mark, Warick Delprado, David Smith, David Pryor, David Galvin, Frank Sullivan, Áine C. Murphy, David Roder, Hany Elsaleh, David Currow, Craig White, Marketa Skala, Kim L. Moretti, Tony Walker, Paolo De Ieso & 5 others Andrew Brooks, Peter Heathcote, Mark Frydenberg, Jeffery Thavaseelan, Susan M. Evans

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: The development, monitoring, and reporting of indicator measures that describe standard of care provide the gold standard for assessing quality of care and patient outcomes. Although indicator measures have been reported, little evidence of their use in measuring and benchmarking performance is available. A standard set, defining numerator, denominator, and risk adjustments, will enable global benchmarking of quality of care.

Objective: To develop a set of indicators to enable assessment and reporting of quality of care for men with localised prostate cancer (PCa).

Design, setting, and participants: Candidate indicators were identified from the literature. An international panel was invited to participate in a modified Delphi process. Teleconferences were held before and after each voting round to provide instruction and to review results.

Outcome measurements and statistical analysis: Panellists were asked to rate each proposed indicator on a Likert scale of 1–9 in a two-round iterative process. Calculations required to report on the endorsed indicators were evaluated and modified to reflect the data capture of the Prostate Cancer Outcomes Registry–Australia and New Zealand (PCOR-ANZ).

Results and limitations: A total of 97 candidate indicators were identified, of which 12 were endorsed. The set includes indicators covering pre-, intra-, and post-treatment of PCa care, within the limits of the data captured by PCOR-ANZ.

Conclusions: The 12 endorsed quality measures enable international benchmarking on the quality of care of men with localised PCa. Reporting on these indicators enhances safety and efficacy of treatment, reduces variation in care, and can improve patient outcomes.

Patient summary: PCa has the highest incidence of all cancers in men. Early diagnosis and relatively high survival rates mean issues of quality of care and best possible health outcomes for patients are important. This paper identifies 12 important measurable quality indicators in PCa care.
Original languageEnglish
Pages (from-to)57-63
Number of pages7
JournalEuropean Urology Focus
Volume4
Issue number1
DOIs
Publication statusPublished - 1 Jan 2018

Keywords

  • Prostate cancer
  • Quality indicators
  • Quality measures
  • Clinical registries
  • Population health

Cite this

Nag, Nupur ; Millar, Jeremy ; Davis, Ian D. ; Costello, Shaun ; Duthie, James B. ; Mark, Stephen ; Delprado, Warick ; Smith, David ; Pryor, David ; Galvin, David ; Sullivan, Frank ; Murphy, Áine C. ; Roder, David ; Elsaleh, Hany ; Currow, David ; White, Craig ; Skala, Marketa ; Moretti, Kim L. ; Walker, Tony ; De Ieso, Paolo ; Brooks, Andrew ; Heathcote, Peter ; Frydenberg, Mark ; Thavaseelan, Jeffery ; Evans, Susan M. / Development of indicators to assess quality of care for prostate cancer. In: European Urology Focus. 2018 ; Vol. 4, No. 1. pp. 57-63.
@article{3ff5fa1eccae401e8bfc11923ced563f,
title = "Development of indicators to assess quality of care for prostate cancer",
abstract = "Background: The development, monitoring, and reporting of indicator measures that describe standard of care provide the gold standard for assessing quality of care and patient outcomes. Although indicator measures have been reported, little evidence of their use in measuring and benchmarking performance is available. A standard set, defining numerator, denominator, and risk adjustments, will enable global benchmarking of quality of care.Objective: To develop a set of indicators to enable assessment and reporting of quality of care for men with localised prostate cancer (PCa).Design, setting, and participants: Candidate indicators were identified from the literature. An international panel was invited to participate in a modified Delphi process. Teleconferences were held before and after each voting round to provide instruction and to review results.Outcome measurements and statistical analysis: Panellists were asked to rate each proposed indicator on a Likert scale of 1–9 in a two-round iterative process. Calculations required to report on the endorsed indicators were evaluated and modified to reflect the data capture of the Prostate Cancer Outcomes Registry–Australia and New Zealand (PCOR-ANZ).Results and limitations: A total of 97 candidate indicators were identified, of which 12 were endorsed. The set includes indicators covering pre-, intra-, and post-treatment of PCa care, within the limits of the data captured by PCOR-ANZ.Conclusions: The 12 endorsed quality measures enable international benchmarking on the quality of care of men with localised PCa. Reporting on these indicators enhances safety and efficacy of treatment, reduces variation in care, and can improve patient outcomes.Patient summary: PCa has the highest incidence of all cancers in men. Early diagnosis and relatively high survival rates mean issues of quality of care and best possible health outcomes for patients are important. This paper identifies 12 important measurable quality indicators in PCa care.",
keywords = "Prostate cancer, Quality indicators, Quality measures, Clinical registries, Population health",
author = "Nupur Nag and Jeremy Millar and Davis, {Ian D.} and Shaun Costello and Duthie, {James B.} and Stephen Mark and Warick Delprado and David Smith and David Pryor and David Galvin and Frank Sullivan and Murphy, {{\'A}ine C.} and David Roder and Hany Elsaleh and David Currow and Craig White and Marketa Skala and Moretti, {Kim L.} and Tony Walker and {De Ieso}, Paolo and Andrew Brooks and Peter Heathcote and Mark Frydenberg and Jeffery Thavaseelan and Evans, {Susan M.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.euf.2016.01.016",
language = "English",
volume = "4",
pages = "57--63",
journal = "European Urology Focus",
issn = "2405-4569",
publisher = "European Association of Urology",
number = "1",

}

Nag, N, Millar, J, Davis, ID, Costello, S, Duthie, JB, Mark, S, Delprado, W, Smith, D, Pryor, D, Galvin, D, Sullivan, F, Murphy, ÁC, Roder, D, Elsaleh, H, Currow, D, White, C, Skala, M, Moretti, KL, Walker, T, De Ieso, P, Brooks, A, Heathcote, P, Frydenberg, M, Thavaseelan, J & Evans, SM 2018, 'Development of indicators to assess quality of care for prostate cancer', European Urology Focus, vol. 4, no. 1, pp. 57-63. https://doi.org/10.1016/j.euf.2016.01.016

Development of indicators to assess quality of care for prostate cancer. / Nag, Nupur; Millar, Jeremy; Davis, Ian D.; Costello, Shaun; Duthie, James B.; Mark, Stephen; Delprado, Warick; Smith, David; Pryor, David; Galvin, David; Sullivan, Frank; Murphy, Áine C.; Roder, David; Elsaleh, Hany; Currow, David; White, Craig; Skala, Marketa; Moretti, Kim L.; Walker, Tony; De Ieso, Paolo; Brooks, Andrew; Heathcote, Peter; Frydenberg, Mark; Thavaseelan, Jeffery; Evans, Susan M.

In: European Urology Focus, Vol. 4, No. 1, 01.01.2018, p. 57-63.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Development of indicators to assess quality of care for prostate cancer

AU - Nag, Nupur

AU - Millar, Jeremy

AU - Davis, Ian D.

AU - Costello, Shaun

AU - Duthie, James B.

AU - Mark, Stephen

AU - Delprado, Warick

AU - Smith, David

AU - Pryor, David

AU - Galvin, David

AU - Sullivan, Frank

AU - Murphy, Áine C.

AU - Roder, David

AU - Elsaleh, Hany

AU - Currow, David

AU - White, Craig

AU - Skala, Marketa

AU - Moretti, Kim L.

AU - Walker, Tony

AU - De Ieso, Paolo

AU - Brooks, Andrew

AU - Heathcote, Peter

AU - Frydenberg, Mark

AU - Thavaseelan, Jeffery

AU - Evans, Susan M.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: The development, monitoring, and reporting of indicator measures that describe standard of care provide the gold standard for assessing quality of care and patient outcomes. Although indicator measures have been reported, little evidence of their use in measuring and benchmarking performance is available. A standard set, defining numerator, denominator, and risk adjustments, will enable global benchmarking of quality of care.Objective: To develop a set of indicators to enable assessment and reporting of quality of care for men with localised prostate cancer (PCa).Design, setting, and participants: Candidate indicators were identified from the literature. An international panel was invited to participate in a modified Delphi process. Teleconferences were held before and after each voting round to provide instruction and to review results.Outcome measurements and statistical analysis: Panellists were asked to rate each proposed indicator on a Likert scale of 1–9 in a two-round iterative process. Calculations required to report on the endorsed indicators were evaluated and modified to reflect the data capture of the Prostate Cancer Outcomes Registry–Australia and New Zealand (PCOR-ANZ).Results and limitations: A total of 97 candidate indicators were identified, of which 12 were endorsed. The set includes indicators covering pre-, intra-, and post-treatment of PCa care, within the limits of the data captured by PCOR-ANZ.Conclusions: The 12 endorsed quality measures enable international benchmarking on the quality of care of men with localised PCa. Reporting on these indicators enhances safety and efficacy of treatment, reduces variation in care, and can improve patient outcomes.Patient summary: PCa has the highest incidence of all cancers in men. Early diagnosis and relatively high survival rates mean issues of quality of care and best possible health outcomes for patients are important. This paper identifies 12 important measurable quality indicators in PCa care.

AB - Background: The development, monitoring, and reporting of indicator measures that describe standard of care provide the gold standard for assessing quality of care and patient outcomes. Although indicator measures have been reported, little evidence of their use in measuring and benchmarking performance is available. A standard set, defining numerator, denominator, and risk adjustments, will enable global benchmarking of quality of care.Objective: To develop a set of indicators to enable assessment and reporting of quality of care for men with localised prostate cancer (PCa).Design, setting, and participants: Candidate indicators were identified from the literature. An international panel was invited to participate in a modified Delphi process. Teleconferences were held before and after each voting round to provide instruction and to review results.Outcome measurements and statistical analysis: Panellists were asked to rate each proposed indicator on a Likert scale of 1–9 in a two-round iterative process. Calculations required to report on the endorsed indicators were evaluated and modified to reflect the data capture of the Prostate Cancer Outcomes Registry–Australia and New Zealand (PCOR-ANZ).Results and limitations: A total of 97 candidate indicators were identified, of which 12 were endorsed. The set includes indicators covering pre-, intra-, and post-treatment of PCa care, within the limits of the data captured by PCOR-ANZ.Conclusions: The 12 endorsed quality measures enable international benchmarking on the quality of care of men with localised PCa. Reporting on these indicators enhances safety and efficacy of treatment, reduces variation in care, and can improve patient outcomes.Patient summary: PCa has the highest incidence of all cancers in men. Early diagnosis and relatively high survival rates mean issues of quality of care and best possible health outcomes for patients are important. This paper identifies 12 important measurable quality indicators in PCa care.

KW - Prostate cancer

KW - Quality indicators

KW - Quality measures

KW - Clinical registries

KW - Population health

UR - http://www.scopus.com/inward/record.url?scp=85048625384&partnerID=8YFLogxK

U2 - 10.1016/j.euf.2016.01.016

DO - 10.1016/j.euf.2016.01.016

M3 - Article

VL - 4

SP - 57

EP - 63

JO - European Urology Focus

JF - European Urology Focus

SN - 2405-4569

IS - 1

ER -